<DOC>
	<DOCNO>NCT01358175</DOCNO>
	<brief_summary>This study ass efficacy safety secukinumab patient active ankylose spondylitis intolerant inadequate response NSAIDs , DMARDs / TNFα inhibitor therapy .</brief_summary>
	<brief_title>16 Week Efficacy 2 Year Long Term Safety Efficacy Secukinumab Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Male nonpregnant , nonlactating female patient least 18 year age Diagnosis moderate severe AS prior document radiologic evidence ( Xray ) fulfil Modified New York criterion AS ( 1984 ) Patients NSAIDs inadequate response Patients regularly take NSAIDs part AS therapy require stable dose Patients antiTNFα agent ( one ) must experience inadequate response Exclusion criterion : Chest Xray evidence ongoing infectious malignant process Patients total ankylosis spine Patients previously treat biological immunomodulating agent except target TNFα Previous treatment celldepleting therapy Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>AS</keyword>
	<keyword>ASAS</keyword>
	<keyword>inflammatory back pain</keyword>
</DOC>